Pathophysiology of chronic graft versus host disease

Chronic Graft Versus Host Disease: Interdisciplinary Management

Volumn , Issue , 2009, Pages 17-30

  Schultz, Kirk R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78149409338     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511576751.004     Document Type: Chapter

References (175)

1. Ozawa S, Nakaseko C, Nishimura M, et al. Chronic graft-versus- host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol. 2007 Apr;137(2):142–151.
2. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol. 2006 Jan;43(1):3–10.
3. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graftversus- host disease, a model for human scleroderma. J Invest Dermatol. 2007 Feb;127(2):281–292.
4. Chen W, Chatta GS, Rubin WD, et al. T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis. J Immunol. 1998 Jul 15;161(2):909–918.
5. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006 Apr 1;107(7):2993–3001.
6. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000 Jun 22;342(25):1846–1854.
7. Frangoul H, Nemecek ER, Billheimer D, et al. A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood. 2007 Dec 15;110(13):4584–4587.
8. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant. 2007 Dec;13(12):1461–1468. Epub2007 Oct 10.
9. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007 Aug 15;110(4):1397–1400. Epub2007 May 2.
10. Buzzeo MP, Yang J, Casella G, Reddy V. Hematopoietic stem cell mobilization with G-CSF induces innate inflammation yet suppresses adaptive immune gene expression as revealed by microarray analysis. Exp Hematol. 2007 Sep;35(9):1456–1465.
11. Talarn C, Urbano-Ispizua A, Martino R, et al. G-CSF increases the number of peripheral blood dendritic cells CD16+ and modifies the expression of the costimulatory molecule CD86+. Bone Marrow Transplant. 2006 May;37(9):873–879.
12. Garderet L, Dulphy N, Douay C, et al. The umbilical cord blood alphabeta T-cell repertoire: characteristics of a polyclonal and naive but completely formed repertoire. Blood. 1998 Jan 1;91(1):340–346.
13. Canaday DH, Chakravarti S, Srivastava T, et al. Class II MHC antigen presentation defect in neonatal monocytes is not correlated with decreased MHC-II expression. Cell Immunol. 2006Oct;243(2):96–106.
14. Shier LR, Schultz KR, Imren S, et al. Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derivedhematopoietic and immune cell populations in healthy humandonors. Biol Blood Marrow Transplant. 2004 Sep;10(9):624–634.
15. Ringden O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004 Feb 1;22(3):416– 423. Epub2003 Dec 22.
16. Bacigalupo A, Lamparelli T, Barisione G, et al; Gruppo Italiano Trapianti Midollo Osseo (GITMO). Thymoglobulin preventschronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.Biol Blood Marrow Transplant. 2006 May;12(5):560–565.
17. Siegal D, Xu W, Sutherland R, et al. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant. 2008 Mar 31. Epub ahead of print.
18. Hale G, Zhang MJ, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998 Dec 15;92(12):4581–4590.
19. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.Blood. 2004 Dec 15;104(13):3865–3871.
20. Pavletic SZ, Carter SL, Keman NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106:3308–3313.
21. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant. 2008 Apr;14(4):458–468.
22. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(12):674–682.
23. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051.
24. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus- leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103:347–352.
25. Yamashita K, Choi U, Woltz PC, et al. Severe chronic graft- versus- host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood. 2004 May 15;103(10):3986–3988. Epub2004 Feb 5.
26. Petersen SL, Ryder LP, Bjork P, et al. A comparison of T-, Band NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors. Bone Marrow Transplant. 2003 Jul;32(1):65–72.
27. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003 Jul 15;102(2):756– 762. Epub 2003 Mar 27.
28. Larsson K, Aschan J, Remberger M, Ringden O, Winiarski J, Ljungman P. Reduced risk for extensive chronic graft-versushost disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. Transplantation. 2004 Feb 27;77(4):526–531.
29. Wojnar J, Giebel S, Holowiecka-Goral A, et al. The incidence and risk factors for chronic graft-versus-host-disease. Ann Transplant. 2006;11(2):14–20; discussion 32–43.
30. Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood. 2003 Nov 15;102(10):3822–3828. Epub 2003 Jul 17.
31. Schmid I, Stachel D, Pagel P, Albert MH. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant. 2008 Apr;14(4):438–444.
32. van Els CA, Bakker A, Zwinderman AH, Zwaan FE, van Rood JJ, Goulmy E. Effector mechanisms in graft-versushost disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. Transplantation. 1990 Jul;50(1):62–66.
33. de Bueger M, Bakker A, Bontkes H, van Rood JJ, Goulmy E. High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA-identical BMT: absence of correlation with GVHD. Bone Marrow Transplant. 1993 May;11(5):363–368.
34. Via CS, Rus V, Gately MK, Finkelman FD. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versushost disease. J Immunol. 1994;153:4040–4047.
35. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000;105:1289–1298.
36. Liu J, Anderson BE, Robert ME, et al. Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease. Blood. 2001;98:3367–3375.
37. Nakamura K, Amakawa R, Takebayashi M, et al. IL-4-producing CD8(+) T cells may be an Immunological hallmark of chronic GVHD. Bone Marrow Transplant. 2005;36:639–647.
38. Silva MG, Ferreira Neto L, Guimaraes A, Machado A, Parreira A, Abecasis M. Long-term follow-up of lymphocyte populations and cellular cytokine production in patients with chronic graft-versus-host disease treated with extracorporeal photopheresis. Haematologica. 2005;90:565–567.
39. Darvay A, Salooja N, Russell-Jones R. The effect of extracorporeal photopheresis on intracellular cytokine expression in chronic cutaneous graft-versus-host disease. J Eur Acad Dermatol Venereol. 2004 May;18(3):279–284.
40. Ritchie D, Seconi J, Wood C, Walton J, Watt V. Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versushost disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:706–712.
41. Cavet J, Dickinson AM, Norden J, et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versushost disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98:1594–1600.
42. Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, Lange A. Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2005 Mar;90(3):425–426.
43. Puliaev R, Nguyen P, Finkelman FD, Via CS. Differential requirement for IFN-gamma in CTL maturation in acute murine graft-versus-host disease. J Immunol. 2004 Jul 15;173(2):910–919.
44. Asavaroengchai W, Wang H, Wang S, et al. An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007 Jan;13(1):46–55.
45. Kim JH, Choi EY, Chung DH. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppressgraft-versus-host disease by producing IFN-gamma and IL-4. J Immunol. 2007 Nov 15;179(10):6579–6587.
46. Badovinac VP, Porter BB, Harty JT. CD8+ T cell contraction is controlled by early inflammation. Nat Immunol. 2004 Aug;5(8):809–817.
47. Sashida G, Ohyashiki JH, Kubota N, et al. Marked telomere fluctuation of leukocytes during graft-versus-host disease in allogeneic stem cell transplantation. Int J Mol Med. 2005 Nov;16(5):883–888.
48. Yamashita K, Choi U, Woltz PC, et al. Severe Chronic Graft-Versus- host Disease is characterized by a Preponderance of CD4+ Effector Memory Cells Relative to Central Memory Cells. Blood. 2004;103(10):3986–3988.
49. Xystrakis E, Bernard I, Dejean AS, Alsaati T, Druet P, Saoudi A. Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RC high but not the CD45RC low subset. Eur J Immunol. 2004;34(2):408–417.
50. Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002 Jun 15;359(9323):2078–2083.
51. Patey-Mariaud de Serre N, Reijasse D, Verkarre V, et al. Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children. Bone Marrow Transplant. 2002 Feb;29(3):223–230.
52. Kotani A, Ishikawa T, Matsumura Y, et al. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versushost disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood. 2001 Nov 15;98(10):3162–3164.
53. Sasaki M, Hasegawa H, Kohno M, Inoue A, Ito MR, Fujita S. Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development ofchronic graft-versus-host disease in mice. J Immunol. 2003 Jan 1;170(1):588–596.
54. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001 Sep 1;98(5):1594–1600.
55. Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation. 2003Dec 27;76(12):1742–1749.
56. Rocha V, Franco RF, Porcher R, et al. Host defense and inflammatorygene polymorphisms are associated with outcomesafter HLA-identical sibling bone marrow transplantation. Blood. 2002 Dec 1;100(12):3908–3918.
57. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003 Dec 4;349(23):2201–2210.
58. Zhang Y, Hexner E, Frank D, Emerson SG. CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease. J Immunol. 2007 Sep 1;179(5):3305–3314.
59. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006 Apr 1;107(7):2993– 3001. Epub2005 Dec 13.
60. Sakoda Y, Hashimoto D, Asakura S, et al. Donor-derived thymic- dependent T cells cause chronic graft-versus-host disease. Blood. 2007 Feb 15;109(4):1756–1764. Epub 2006 Oct 10.
61. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001 Mar 1;97(5):1458–1466.
62. Fallen PR, McGreavey L, Madrigal JA, et al. Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant. 2003 Nov;32(10):1001–1014.
63. Wysoczanska B, Bogunia-Kubik K, Dlubek D, et al. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Transplant Proc. 2007 Nov;39(9):2898–2901.
64. Clave E, Rocha V, Talvensaari K, et al. Prognostic value of pretransplantation host thymic function in HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2005 Mar 15;105(6):2608–2613.
65. Sullivan K, Storb R, Buckner D, Fefer A. Graft-versus host disease as adoptic immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med. 1989;320:828–834.
66. Ordermann R, Hutchinson R, Friedman J, et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Inv. 2002;109:1249–1256.
67. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft- versus host disease with autoimmune manifestations. Blood. 2006;107:2993–3001.
68. Schlomchik WD, Couzens MS, Tang CB, et al. Preventation of graft-versus host disease by inactivation of host antigen- presenting cells. Science. 1999;285:412–415.
69. Lang TJ, Nguyen P, Peach R, Grause WC, Via CS. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function. J Immunol. 2002;168:3786–3792.
70. Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant. 1995;16:289–295.
71. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004;199:1133–1142.
72. Perruche S, Marandin A, Kleinclauss F, et al. Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence. Transplantation. 2006 Feb 27;81(4):573–582.
73. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroidrefractory chronic graft-versus-host disease. Blood. 2006 Jul 15;108(2):756–762. Epub 2006 Mar 21.
74. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505–511.
75. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapyrefractory chronic graft-versus-host disease. Blood. 2004 Oct 15;104(8):2603–2606.
76. Blazar BR, Krieg AM, Taylor PA. Synthetic unmethylated cytosine- phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia response in naive and bone marrow transplant recipients. Blood. 2001;98:1217–1225.
77. Schultz KR, Su WN, Hsiao CC, et al. Chloroquine prevention of murine MHC-disparate acute graft-versus host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T cell cytokine production. Biol Blood and Marrow Transplant. 2002;8:648–655.
78. MacFarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol. 1998;160:1122–1131.
79. She K, Gilman AL, Aslanian S, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007 Apr;13(4):386–397. Epub 2007 Feb 15.
80. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: upregulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101:4500–4504.
81. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004;103:353–359.
82. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105:2973–2978.
83. Brink R. 2006. Regulation of B cell self-tolerance by BAFF. Semin Immunol18:276–283.
84. Tangye SG, Bryant VL, Cuss AK, Good KL 2006. BAFF, APRIL and human B cell disorders. Semin Immunol18:305–317.
85. Zhang J, Roscke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 2001;166:6–10.
86. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44:1313–1319.
87. Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007 Oct 15;13(20):6107–6114.
88. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group. Blood. 2008 Mar 15;111(6):3276–3285. Epub 2007 Oct 9.
89. Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R. IRTAs: a new family of immunoglobulin-like receptors differentially expressed in B cells. Blood. 2002 Apr 15;99(8):2662–2669.
90. Kochi Y, Yamada R, Suzuki A, et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities [Erratum in: Nat Genet. 2005 Jun;37(6):652] Nat Genet. 2005 May;37(5):478– 485. Epub2005 Apr 17.
91. Shimada M, Onizuka M, Machida S, et al. Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. Br J Haematol. 2007 Nov;139(3):458– 463. Epub2007 Sep 14.
92. Chistiakov DA, Chistiakov AP. Is FCRL3 a new general autoimmunity gene? Hum Immunol. 2007 May;68(5):375–383. Epub 2007 Feb 15. Review.
93. Greinix HT, Pohlreich D, Kouba M, et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008 Feb;14(2):208–219.
94. Vossen JM, Heidt PJ, van den Berg H, Hermans J, Dooren LJ. Preventation of infection and graft-versus host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis. 1990;9:14–23.
95. Taylor PA, Friedman TM, Korngold R, Noelle R, Blazar BR. Tolerance induction of alloreactive T cells via ex vivo blockade of CD40:CD40L co-stimulatory pathway results in the generation of potent immune regulatory cell. Blood. 2002;99:4601–4609.
96. Lang TJ, Nguyen P, Peach R, Gause WC, Via CS. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function. J Imm. 2002;168:3786–3792.
97. Gilman AL, Chan KW, Mogul M, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:327–334.
98. Schultz KR, Bader S, Paquet J, Li W. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. Blood. 1995 Dec 1;86(11):4344–4352.
99. Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation. 1984 Nov;38(5):465–458.
100. Soderberg C, Sumitran-Karuppan S, Ljungman P, Moller E. CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Transplantation. 1996 Feb 7;61(4):594–600.
101. Soderberg C, Larsson S, Rozell BL, Sumitran-Karuppan S, Ljungman P, Moller E. Cytomegalovirus-induced CD13- specific autoimmunity-a possible cause of chronic graft-vshost disease. Transplantation. 1996 Feb 27;61(4):600–609.
102. Naucler CS, Larsson S, Moller E. A novel mechanism for virusinduced autoimmunity in humans. Immunol Rev. 1996; 152: 175–92.74a.
103. Hildebrandt GC, Granell M, Urbano-Ispizua A, et al. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan;14(1):67–74.
104. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med. 1999 Jul;5(7):839–842.
105. Gallardo D, Arostegui JI, Balas A, et al. GvHD Subcommittee of the Grupo Espanol de Trasplante Hemapoyetico (GETH).Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation. Br J Haematol. 2001 Sep;114(4):931–936
106. Lin MT, Gooley T, Hansen JA, et al. Absence of statistically significant correlation between disparity for the minor histocompatibility antigen-HA-1 and outcome after allogeneic hematopoietic cell transplantation. Blood. 2001 Nov 15;98(10):3172–3173.
107. Grumet FC, Hiraki DD, Brown BWM, et al. D31 mismatching affects marrow transplantation outcome. Biol Blood Marrow Transplant. 2001;7(9):503–512. 108. Flowers ME, Pepe MS, Longton G, et al. Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol. 1990;74:492–496.
108. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051.
109. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graftvers s- leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103:347–352.
110. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004;103:353–359.
111. Miklos DB, Kim HT, Miller KH, et al. Antibody Responses to H-Y Minor Histocompatibility Antigens Correlate with Chronic Graft versus Host Disease and Disease Remission. Blood. 2005;105:2973–2978.
112. Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol. 2006;34:389–396.
113. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation. 1988;46:238–240.
114. Quaranta S, Shulman H, Ahmed A, et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol. 1999; 91:106–116.
115. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin. Lab. Haem. 2005;27:247–249.
116. Graze PR, Gale RP. Chronic graft versus host disease: a syndrome of disordered immunity. Am J Med.1979 Apr;66(4):611–620.
117. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980 Aug;69(2):204–217.
118. Quaranta S, Shulman H, Ahmed A, et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol. 1999 Apr;91(1):106–116.
119. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001 Mar 1;97(5):1196–1201.
120. Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood2007:110, 237–241.
121. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodiesto the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667–2676.
122. Sambo P, Baroni SS, Luchetti M, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001;44:2653–2664.
123. Taylor PA, Lees CJ, Blazar, BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493–3499.
124. Hoffmann P, Ermann J Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389–399.
125. Young KJ, DuTemple B, Phillips MJ, Zhang L. Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol. 2003 Jul;171(1):134–41.
126. Clark FJ, Gregg R, Piper K, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25 high regulatory T cells. Blood. 2004;103(6):2410–2416.
127. Miura Y, Thoburn CJ, Bright EC, et. al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 2004;104(7):2187–2193.
128. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graftversus- host disease. Blood. 2005;106(8):2903–2911.
129. Sanchez J, Casano J, Alvarez MA, et al. Kinetic of regulatory CD25 high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. 2004;126(5):697–703.
130. Meignin V, Peffault de Latour R, Zuber J, et al. Numbers of Foxp3-expressing CD4+CD25 high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol. 2005;33(8):894–900.
131. Rieger K, Loddenkemper C, Maul J, et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood. 2006 Feb 15;107(4):1717–1723. Epub 2005 Nov 8.
132. Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant. 2003 Mar;9(3):170–176.
133. Clark FJ, Freeman L, Dzionek A, et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation. 2003 Jan 27;75(2):221–225.
134. Waller EK, Rosenthal H, Sagar L. DC2 effect on survival following allogeneic bone marrow transplantation. Oncology (Huntingt). 2002 Jan;16(1 Suppl 1):19–26.
135. Rajasekar R, Mathews V, Lakshmi KM, et al. Plasmacytoid dendriticcell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD. Biol Blood Marrow Transplant. 2008 Mar;14(3):344–350.
136. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen- presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005 Mar 1;105(5):2227–2234. Epub 2004 Nov 2.
137. Sato M, Tokuda N, Fukumoto T, Mano T, Sato T, Ueyama Y. Immunohistopathological study of the oral lichenoid lesions of chronic GVHD. J Oral Pathol Med. 2006 Jan;35(1):33–36.
138. Soares AB, Faria PR, Magna LA, et al. Chronic GVHD in minor salivary glands and oral mucosa: histopathological and immunohistochemical evaluation of 25 patients. J Oral Pathol Med. 2005 Jul;34(6):368–373.
139. Park HJ, Kim JE, Lee JY, et al. Increased expression of IL-18 in cutaneous graft-versus-host disease. Immunol Lett. 2004 Aug 15;95(1):57–61.
140. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980 Aug;69(2):204–217.
141. Or R, Gesundheit B, Resnick I, et al. Sparing effect by ontelukasttreatment for chronic graft versus host disease: a pilotstudy. Transplantation. 2007 Mar 15;83(5):577–581.
142. Ilan Y, Ohana M, Pappo O, et al. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity. Transplantation. 2007 Feb 27;83(4):458–467.
143. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001 May 15;97(10):2923–2931.
144. Larghero J, Rocha V, Porcher R, et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants. Br J Haematol. 2007 Jul;138(1):101–109.
145. Ferrara JLM, Deeg HJ. GVHD review article. N Engl Med J. 1991;324:667–674.
146. Facon T, Jouet JP, Noel-Walter, Bloget F, Bauters F, Janin A. Involvement of TNF-alpha secreting macrophages in lethal forms of human graft-vs.-host disease. Bone Marrow Transplant. 1997;20:511–515.
147. Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplant. 1990;5:69–82.
148. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graftversus- host disease. Transplantation. 1999 Jan 15;67(1):59–65.
149. New JY, Li B, Koh WP, et al. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant. 2002;29:979–986.
150. Hildebrandt GC, Duffner UA, Olkiewicz KM, et al. Acritical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrowtransplantation. Blood. 2004;103:2417–2426.
151. Banovic T, MacDonald KP, Morris ES, et al. TGF-β in allogeneic stem cell transplantation: friend or foe? Blood. 2005;106:2206–2214.
152. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307–336.
153. Foley R, Couban S, Walker I, et al. Monitoring soluble interleukin- 2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;21:769–773.
154. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant. 1998;21:29–32.
155. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graftversus- host disease. Bone Marrow Transplant. 1996;17:185–190.
156. Kobayashi S, Imamura M, Hashino S, Tanaka J, Asaka M. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leuk Lymphoma. 1997;28:159–169.
157. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation. 1998;66:863–871.
158. Campen DH, Horwitz DA, Quismorio FP Jr, EhresmannGR, Martin WJ. Serum levels of IL-2 receptor and activity of rheumatic disease characterized by immune activation. Arthr Rheum. 1988;31:1358–1364.
159. Hayashi T, Morishita E, Ontachi Y, et al. Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report. Am J Hematol. 2006 Feb;81(2):121–123.
160. Chang DM, Wang CJ, Kuo SY, Lai JH. Cell surface markers and circulating cytokines in graft versus host disease. Immunol Invest. 1999 Jan;28(1):77–86.
161. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. BiomarkerWorking Group Report. Biol Blood Marrow Transplant. 2006Feb;12(2):126–137.
162. Martin PJ, Weisdorf D, Przepiorka D, et al. Design of Clinical Trials Working Group. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006May;12(5):491–505.
163. Filipovich A, Weisdorf D, Pavletic S, et al. Diagnosis And Scoring Of Chronic Graft Versus Host Disease NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: I. Diagnosis and Staging Working Group Report National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2005;11:945–956.
164. Pavletic SZ, Martin P, Lee SJ, et al. Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2006 Mar;12(3):252–266.
165. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with bloodstem cell transplantation. Blood. 2001;97:3380–3389.
166. Tayebi H, Tiberghien P, Ferrand C, et al. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T-cell compartment homeostasis than bone marrow transplantation.Bone Marrow Transplant. 2001;27:167–175.
167. Robinet E, Lapierre V, Tayebi H, Kuentz M, Blaise D, Tiberghien P. Blood versus marrow hematopoietic allogeneic graft. Transfus Apher Sci. 2003 Aug;29(1):53–59.
168. Lapierre V, Oubouzar N, Auperin A, et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood. 2001;97:2580–2586.
169. Lapierre V, Auperin A, Tayebi H, et al. Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony- stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. Blood. 2002;100:1484–1489.
170. Tayebi H, Lapierre V, Saas P, et al. Enhanced activation of B cells in a granulocyte colony-stimulating factor- mobilized peripheral blood stem cell graft. Br J Haematol. 2001; 114:698–700.
171. Morikawa K, Miyawaki T, Oseko F, Morikawa S, Imai K. G-CSF enhances the immunoglobulin generation rather than the proliferation of human B lymphocytes. Eur J Haematol. 1993;51:144–151.
172. Ng LG, Ng CH, Woehl B, et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur J Immunol. 2006 Jul;36(7):1837–1846.
173. Katsenelson N, Kanswal S, Puig M, Mostowski H, Verthelyi D, Akkoyunlu M. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur J Immunol. 2007 Jul;37(7):1785–1795.
174. Granell M, Urbano-Ispizua A, Arostegui JI, et al. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. Haematologica. 2006 Oct;91(10):1372–1376.
175. Tikkanen JM, Hollmen M, Nykanen AI, Wood J, Koskinen PK, Lemstrom KB. Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. Am J Respir Crit Care Med. 2006 Nov 15;174(10):1145–1152. Epub2006 Aug 17